[O-06] Oral Session 06

[O-06-5] Long-term safety and efficacy of efgartigimod in patients with gMG: interim results from ADAPT-SC+

Akiyuki Uzawa¹, James F Howard, Jr², George Li³, Vuan Vu⁴, Temur Margania⁵, Denis Korobko⁶, Marek Smilowski⁷, Krzysztof Banaszkiewicz⁸, Li Liu⁹, Sophie Steeland⁹, Jan Noukens¹⁰, Benjamin Van Hoorick⁹, Jana Podhorna⁹, Yuebing Li¹¹, Kimiaki Utsugisawa¹², Francesco Sacca¹³, Heinz Wiendl¹⁴, Jan De Bleecker¹⁵, Renato Mantegazza¹⁶ (1.Chiba University Hospital, Neurology, Japan, 2.The University of North Carolina, USA, 3.Medsol Clinical Research Center Inc, USA, 4.University of South Florida Morsani College of Medicine, USA, 5.New Hospitals, Georgia, 6.State Budgetary Healthcare Institution of Novosibirsk Region "State Novosibirsk Regional Clinical Hospital", Russia, 7.Medical University of Silesia, Poland, 8.Krakowski Szpital Specjalistyczny im. Jana Pawla II, Poland, 9.argenx, Belgium, 10.Curare Consulting BV, Netherlands, 11.Cleveland Clinic, USA, 12.Hanamaki General Hospital, Neurology, Japan, 13.Federico II University of Naples, Italy, 14.University of Munster, Germany, 15.Ghent University Hospital, Belgium, 16.Fondazione Istituto Neurologico Carlo Besta, Italy)